

# HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF TADALAFIL AND SILDENAFIL IN BULK AND TABLET DOSAGE FORM

Mayur S. Jain<sup>1\*</sup>, Dr. Shailesh K. Koradia<sup>2</sup>

<sup>1\*,2</sup>Department Of Pharmaceutical Chemistry And Quality Assurance Krishna School Of Pharmacy And Research,Drs Kiran And Pallavi Patel Global University Vadodara ,India Mob. No: 9405801990

**\*Corresponding Author:** Mayur S. Jain

\*Email id: mayurjain176@gmail.com

## Abstract

The current work aims to establish a validated RP-HPLC method for estimating the combined dosage of sildenafil and tadalafil. Using ZORBAX C18 (250 x 4.6, 5  $\mu$ ) as a stationary phase and mobile phase, the medicines were separated appropriately: Acetate Buffer: Methanol 10:90 with a mobile phase flow rate of 0.7 mL/min., at 280 nm detection was carried out. Sildenafil's  $R_t$  was 4.611 minutes, while Tadalafil's was 3.744 minutes. Tadalafil and sildenafil had respective percentage drug contents of 98.63% when the commercial formulation was examined using the established approach. In the 50–150 PPM range for Tadalafil and 50–150 PPM range for Sildenafil, the approach was determined to be linear.. The results showed that the quantitation limit for sildenafil was 1.65 PPM and the detection limit for tadalafil was 5 PPM. For both medications, the accuracy and precision scores were found to be close to 100% w/w. Additionally, the approach was proven to be specific and robust. Tadalafil and sildenafil in combination dosage form were found to be linear, specific, sensitive, precise, accurate, and robust when analyzed using the proposed RP-HPLC technique.


**Keyword:** Tadalafil and Sildenafil, HPLC, Validation

## Introduction

Tadalafil is a crystalline powder that ranges from white to off white. It is soluble in methanol and just weakly soluble in water. Tadalafil has a molecular weight of 438.4 g/mol and the chemical formula is C<sub>22</sub>H<sub>19</sub>N<sub>3</sub>O<sub>4</sub>. Tadalafil is quickly absorbed when taken orally. Within 30 to 120 minutes, the plasma concentration reaches its maximum. The cytochrome P450 enzyme system breaks down tadalafil in the liver. 17.5 hours is the elimination half-life. One type of PDE5 inhibitor is tadalafil. One enzyme that degrades cGMP is PDE5. One signaling molecule involved in erectile function is cGMP. Tadalafil helps to raise the amounts of cGMP in the penis, which results in an erection, by preventing the breakdown of cGMP.


**Table 1: Drug profile for Tadalafil**

| Drug Name         | Tadalafil   |
|-------------------|---|
| Brand Name        | Cialis  |
| Class             | Phosphodiesterase type 5 (PDE5) inhibitor   |
| Indications       | Erectile dysfunction, benign prostatic hyperplasia (BPH)  |
| Dosage            | 2.5-20 mg orally once daily   |
| Contraindications | Heart disease, liver disease, kidney disease, nitrate Medications   |
| Precautions       | Use with caution in people with diabetes, high blood pressure, and bleeding disorders                                     |
| Overdose          | Symptoms may include headache,flushing.and upset stomach.seek inmedical attention if you experience any of these symptoms |
| Storage           | Store at room temperature in a dry place  |

|           |   |  |
|-----------|---|--|
| Structure |                                   |  |
| IUPAC     | (6R,12Ar)-6-(1,3-Benzodioxol-5yl)-2-methyl-1,2,3,6,7,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione. |  |

**Sildenafil** is a crystalline powder that ranges from White of- white. It is soluble in methanol and just weakly soluble in water. Sildenafil's molecular weight is 474.6 g/mol and its chemical formula is C<sub>22</sub>H<sub>30</sub>N<sub>6</sub>O<sub>4</sub>S. When sildenafil is taken orally, it is quickly absorbed. Within 30 to 120 minutes, the plasma concentration reaches its maximum. The cytochrome P450 enzyme system breaks down sildenafil in the liver. Three to five hours is the elimination half-life. One PDE5 inhibitor is sildenafil. One enzyme that degrades cGMP is PDE5. One signaling molecule involved in erectile function is cGMP. Sildenafil helps to raise the amounts of cGMP in the penis, which results in an erection, by preventing the breakdown of cGMP.

**Table 2: Drug profile for Sildenafil**

|                          |   |
|--------------------------|---|
| <b>Drug Name</b>         | <b>Sildenafil</b>   |
| <b>Brand Name</b>        | Viagra  |
| <b>Class</b>             | Phosphodiesterase type 5 (PDE5) inhibitor   |
| <b>Indications</b>       | Erectile dysfunction, benign prostatic hyperplasia (BPH)  |
| <b>Dosage</b>            | 25-100 mg orally 30-60 minutes before sexual activity   |
| <b>Contraindications</b> | Heart disease, liver disease, kidney disease, nitrate Medications   |
| <b>Precautions</b>       | Use with caution in people with diabetes, high blood pressure, and bleeding disorders   |
| <b>Overdose</b>          | Symptoms may encompass cephalalgia, facial erythema, and gastrointestinal distress; it is imperative to pursue medical evaluation should any of these manifestations occur. |
| <b>Storage</b>           | Store in dry place at room temperature  |
| Structure                |   |
| IUPAC                    | 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one;2-hydroxypropane-1,2,3-tricarboxylic acid                         |

## Materials And Methods

### Chemicals and solvents:

HPLC grade methanol (LichrosolR, Merck Life sciences Pvt. Ltd., Mumbai, India), HPLC water 2487 MPOWER 2. Acetate buffer, composed of sodium acetate, acetic acid, and distilled water, was employed in the investigation. The analytical standards for Tadalafil and Sildenafil were graciously provided as a donation from Sigma-Aldrich (USA). The

Sildalist tablet, which comprises 100 mg of Sildenafil and 20 mg of Tadalafil was acquired from the local commercial market, produced by Torrent Pharmaceutical Company.

#### Instrumentation

A UV spectrophotometer with a PDA detector, specifically the Alliance model 2996, was employed in this study to ascertain the  $\lambda$  max values of the pharmaceutical compounds. A non-endcapped ZORBAX C18 column (250 x 4.6 mm, 5  $\mu$ m) was utilized for the purpose of method development. The chromatographic system was operated under the control of Empower analytical software. The analytes were scrutinized through UV detection at a wavelength of 280 nm, utilizing an isocratic mode with the mobile phase consisting of Acetate Buffer and Methanol in a 10:90 ratio; the flow rate was set at 0.7 mL/min. In alignment with the specifications of the flow chamber, the concentration rate was consistently preserved at 1.0 mL/min, while UV absorbance measurements were recorded at 280 nm. The operational temperature of the oven and the duration of the analytical run were regulated at 37°C and 8 minutes, respectively. The ZORBAX C18 column (250 x 4.6 mm, 5  $\mu$ m) was chosen for the formulation of the analytical methodology. The chromatographic apparatus was continuously scrutinized utilizing Empower software. Analytes were discerned via UV absorption at 280 nm in an isocratic configuration, employing a mobile phase consisting of Acetate Buffer and Methanol in a 10:90 volumetric ratio, while sustaining a flow rate of 0.7 mL/min. The flow rate was subsequently adjusted to 1.0 mL/min, and the effluent was evaluated at 280 nm. The operational temperature and the duration of the chromatographic run were maintained at 37°C and 8 minutes, respectively.

**Table3: Optimized conditions of chromatographic work**


| Parameters           | Condition                       |
|----------------------|---------------------------------|
| stationary phase     | ZORBAX C18(250*4.6,5 $\mu$ m)   |
| Mobile phase         | Acetate Buffer : Methanol 10:90 |
| Flow rate            | 0.7 mL/min                      |
| Run Time:            | 8.0 Minutes                     |
| Injection volume     | 20.00 $\mu$ l                   |
| Column Temperature   | 37°C                            |
| Detection wavelength | 280                             |

#### Preparation of standard solution


Standard stock solutions were meticulously formulated at a concentration of 200 PPM by individually solubilizing 20 mg of Sildenafil and 20 mg of Tadalafil in mobile phases, specifically a combination of acetate buffer and methanol in a proportion of 10:90, culminating in a total volume of 100 ml to produce a stock solution with an established concentration of 200 PPM. The aforementioned standard stock solution was then appropriately diluted using suitable diluents to achieve various concentrations of Sildenafil and Tadalafil, specifically 50 PPM, 80 PPM, 100 PPM, 120 PPM, and 150 PPM, for the purpose of establishing linearity.

#### Preparation of Sample Solutions of sildenafil and Tadalafil

A total of twenty tablets were meticulously quantified and subsequently pulverized into a fine particulate form; thereafter, the powdered tablet material corresponding to 20 mg of Sildenafil and 20 mg of Tadalafil was transferred into a clean and dry 100 ml volumetric flask. A diluent was added, and the resulting mixture was subjected to sonication to guarantee thorough dissolution, after which the volume was adjusted to the calibration mark with the diluent. The resultant sample solution underwent filtration, and a suitably diluted sample solution was prepared to attain a concentration of 200 PPM for both Sildenafil and Tadalafil, which was subsequently placed into a 100 ml volumetric flask that was clean and dry. A suitable diluent was introduced, and the resultant solution was subjected to sonication until a state of complete dissolution was achieved, subsequently followed by the calibration of the volume to the designated mark using the diluent. The aforementioned sample solution was filtered and appropriately diluted to attain a concentration of 200 PPM of Sildenafil and 200 PPM of Tadalafil.




|   | Peak Name  | RT    | Area   | % Area | USP Tailing | USP Plate Count |
|---|------------|-------|--------|--------|-------------|-----------------|
| 1 | Tadalafil  | 3.747 |        |        |             |                 |
| 2 | Sildenafil | 4.733 | 963929 | 100.00 | 1.67        | 3356.20         |

**Fig. 1: Normal chromatogram for Sildenafil**


|   | Peak Name | RT    | Area   | % Area | USP Tailing | USP Plate Count |
|---|-----------|-------|--------|--------|-------------|-----------------|
| 1 | Tadalafil | 3.731 | 140994 | 100.00 | 1.32        | 3746.94         |

**Fig. 2: Normal chromatogram for Tadalafil**



|   | Peak Name  | RT    | Area   | % Area | USP Tailing | USP Plate Count | Resolution |
|---|------------|-------|--------|--------|-------------|-----------------|------------|
| 1 | Tadalafil  | 3.741 | 69916  | 11.30  | 1.46        | 4270.63         |            |
| 2 | Sildenafil | 4.702 | 549058 | 88.70  | 1.61        | 2783.07         | 3.39       |

**Fig. 3: Normal chromatogram for Tadalafil and Sildenafil STD mixture**



|   | Peak Name  | RT    | Area   | % Area | USP Tailing | USP Plate Count | Resolution |
|---|------------|-------|--------|--------|-------------|-----------------|------------|
| 1 | Tadalafil  | 3.741 | 69916  | 11.30  | 1.46        | 4270.63         |            |
| 2 | Sildenafil | 4.702 | 549058 | 88.70  | 1.61        | 2783.07         | 3.39       |

**Fig. 4: Normal chromatogram for Tadalafil and Sildenafil Sample mixture**

### Method Validation

The methodology that was formulated has been determined to be in compliance with the validation standards established by the ICH and the FDA, with the validation parameters encompassing specificity, linearity, precision, range, accuracy, robustness, sensitivity (Limit of Quantification & Limit of Detection), and the stability of the solution.


### Linearity

The ability of an analytical methodology to yield test results that are precisely commensurate with the concentration of the analyte present in the sample, within a defined range, is referred to as linearity. For single point standardization, linearity should encompass the target concentration and extend at least 20% beyond the specified range. Using peak area responses, the correlation coefficient, which defines linearity, should be 0.99. A minimum of five distinct concentrations

of the working standard solution (50, 80, 100, 120, and 150 PPM) were prepared, and three replicates of each concentration were then made in order to achieve linearity.

**Table 4: Linearity for Tadalafil**


| S. No. | Conc.in ppm | Area   |
|--------|-------------|--------|
| 1      | 50          | 35176  |
| 2      | 80          | 57932  |
| 3      | 100         | 74280  |
| 4      | 120         | 88656  |
| 5      | 150         | 110049 |



**Fig 5 : Linearity for Tadalafil**

**Table 5: Linearity for Sildenafil**

| SR.NO | CONC. PPM | abs    |
|-------|-----------|--------|
| 1     | 50        | 258322 |
| 2     | 80        | 407259 |
| 3     | 100       | 517853 |
| 4     | 120       | 627931 |
| 5     | 150       | 782604 |



**Fig 6: Linearity for Sildenafil**

**Table 6 :Linearity for Sildenafil**

| S.NO     | SampleName    | Vial | Inj | Name       | RetentionTime(min) | Area     | %Area | USP Tailing | USP Plate count | Plate |
|----------|---------------|------|-----|------------|--------------------|----------|-------|-------------|-----------------|-------|
| 1        | Blank         | 15   | 1   | Sildenafil | 4.707              |          |       |             |                 |       |
| 2        | MixStd-50ppm  | 16   | 1   | Sildenafil | 4.573              | 258322   | 88.01 | 1.71        | 1556.01         |       |
| 3        | MixStd-80ppm  | 17   | 1   | Sildenafil | 4.566              | 407259   | 87.55 | 1.70        | 1525.97         |       |
| 4        | MixStd-100ppm | 18   | 1   | Sildenafil | 4.565              | 517853   | 87.46 | 1.73        | 1509.28         |       |
| 5        | MixStd-120ppm | 19   | 1   | Sildenafil | 4.561              | 627931   | 87.63 | 1.77        | 1527.55         |       |
| 6        | MixStd-150ppm | 20   | 1   | Sildenafil | 4.559              | 782604   | 87.67 | 1.78        | 1527.88         |       |
| Mean     |               |      |     |            | 4.588              | 518793.8 |       |             |                 |       |
| Std.Dev. |               |      |     |            | 0.058              | 201117.7 |       |             |                 |       |
| %RSD     |               |      |     |            | 1.27               | 38.77    |       |             |                 |       |


**Table 7 : Linearity data for Tadalafil**

| SR.NO    | Sample Name   | Vial | Inj | Name      | Retention Time(min) | Area    | %Area | USP Tailing | USP Plate Count |
|----------|---------------|------|-----|-----------|---------------------|---------|-------|-------------|-----------------|
| 1        | Blank         | 15   | 1   | Tadalafil | 3.747               |         |       |             |                 |
| 2        | MixStd-50ppm  | 16   | 1   | Tadalafil | 3.706               | 35176   | 11.99 | 1.36        | 2706.47         |
| 3        | MixStd-80ppm  | 17   | 1   | Tadalafil | 3.705               | 57932   | 12.45 | 1.39        | 2608.58         |
| 4        | MixStd-100ppm | 18   | 1   | Tadalafil | 3.705               | 74280   | 12.54 | 1.42        | 2559.73         |
| 5        | MixStd-120ppm | 19   | 1   | Tadalafil | 3.706               | 88656   | 12.37 | 1.45        | 2414.58         |
| 6        | MixStd-150ppm | 20   | 1   | Tadalafil | 3.706               | 110049  | 12.33 | 1.45        | 2460.28         |
| Mean     |               |      |     |           | 3.713               | 73218.4 |       |             |                 |
| Std.Dev. |               |      |     |           | 0.017               | 28621.8 |       |             |                 |
| %RSD     |               |      |     |           | 0.46                | 39.09   |       |             |                 |

**Accuracy**


The standard solution was spiked in order to assess accuracy. The measurements are taken at the target concentration of tadalafil and sildenafil in Sildalist tablets, as well as at appropriate intervals around this moment.

Recovery tests at three concentration levels 50%, 100%, and 150 percent in which three samples were injected from each concentration were used to assess the assay method's accuracy. For every one of the three replicate samples, the percentage recovery of Tadalafil and Sildenafil was determined.




|   | Peak Name  | RT    | Area   | % Area | USP Tailing | USP Plate Count | Resolution |
|---|------------|-------|--------|--------|-------------|-----------------|------------|
| 1 | Tadalafil  | 3.710 | 35479  | 12.09  | 1.39        | 2517.19         |            |
| 2 | Sildenafil | 4.591 | 257869 | 87.91  | 1.72        | 1456.14         | 2.45       |



**FIG 7: Chromatogram for Tadalafil and Sildenafil Accuracy 50%**

|   | Peak Name  | RT    | Area   | % Area | USP Tailing | USP Plate Count | Resolution |
|---|------------|-------|--------|--------|-------------|-----------------|------------|
| 1 | Tadalafil  | 3.712 | 73971  | 12.38  | 1.45        | 2439.62         |            |
| 2 | Sildenafil | 4.587 | 523414 | 87.62  | 1.74        | 1530.54         | 2.45       |

**FIG 8: Chromatogram for Tadalafil and Sildenafil Accuracy 100 %**

|   | Peak Name  | RT    | Area   | % Area | USP Tailing | USP Plate Count | Resolution |
|---|------------|-------|--------|--------|-------------|-----------------|------------|
| 1 | Tadalafil  | 3.707 | 108588 | 12.09  | 1.44        | 2699.59         |            |
| 2 | Sildenafil | 4.578 | 789296 | 87.91  | 1.74        | 1765.45         | 2.58       |

**FIG9:Chromatogram for Tadalafil and Sildenafil Accuracy 150%**



**Table 8: Accuracy data for Sildenafil**

| S.NO     | Sample Name  | Vial | Inj | Name       | RetentionTime (min) | Area     | %Area | USP Tailing | USP Plate Count |
|----------|--------------|------|-----|------------|---------------------|----------|-------|-------------|-----------------|
| 1        | Blank        | 15   | 1   | Sildenafil | 4.707               |          |       |             |                 |
| 2        | Std          | 16   | 1   | Sildenafil | 4.571               | 519509   | 87.99 | 1.72        | 1485.70         |
| 3        | Std          | 16   | 1   | Sildenafil | 4.575               | 524152   | 88.00 | 1.75        | 1474.42         |
| 4        | Std          | 16   | 1   | Sildenafil | 4.576               | 523255   | 88.03 | 1.74        | 1488.63         |
| 5        | Std          | 16   | 1   | Sildenafil | 4.578               | 521382   | 87.92 | 1.72        | 1472.84         |
| 6        | B.std        | 16   | 1   | Sildenafil | 4.587               | 526001   | 88.12 | 1.73        | 1621.25         |
| 7        | B.std        | 16   | 1   | Sildenafil | 4.582               | 532165   | 88.22 | 1.71        | 1741.91         |
| 8        | Std          | 16   | 1   | Sildenafil | 4.575               | 522418   | 87.89 | 1.74        | 1480.16         |
| 9        | Accuracy50%  | 17   | 2   | Sildenafil | 4.590               | 258703   | 87.89 | 1.71        | 1477.73         |
| 10       | Accuracy50%  | 17   | 2   | Sildenafil | 4.591               | 257869   | 87.91 | 1.72        | 1456.14         |
| 11       | Accuracy50%  | 17   | 1   | Sildenafil | 4.590               | 257587   | 87.74 | 1.70        | 1482.99         |
| 12       | Accuracy50%  | 17   | 1   | Sildenafil | 4.588               | 257082   | 88.17 | 1.69        | 1471.55         |
| 13       | Accuracy100% | 18   | 1   | Sildenafil | 4.587               | 523414   | 87.62 | 1.74        | 1530.54         |
| 14       | Accuracy100% | 18   | 2   | Sildenafil | 4.588               | 523171   | 88.09 | 1.73        | 1579.91         |
| 15       | Accuracy100% | 18   | 2   | Sildenafil | 4.587               | 521500   | 88.05 | 1.73        | 1528.96         |
| 16       | Accuracy100% | 18   | 1   | Sildenafil | 4.590               | 522554   | 87.72 | 1.74        | 1552.58         |
| 17       | Accuracy150% | 19   | 1   | Sildenafil | 4.579               | 784060   | 87.85 | 1.76        | 1656.85         |
| 18       | Accuracy150% | 19   | 1   | Sildenafil | 4.574               | 787677   | 87.89 | 1.76        | 1765.48         |
| 19       | Accuracy150% | 19   | 2   | Sildenafil | 4.578               | 789296   | 87.91 | 1.74        | 1765.45         |
| 20       | Accuracy150% | 19   | 2   | Sildenafil | 4.575               | 787852   | 87.89 | 1.76        | 1701.86         |
| Mean     |              |      |     |            | 4.588               | 523139.2 |       |             |                 |
| Std.Dev. |              |      |     |            | 0.029               | 176490.8 |       |             |                 |
| %RSD     |              |      |     |            | 0.63                | 33.74    |       |             |                 |


**Table 9 : Accuracy data for Tadalafil**

| S.NO     | Sample Name  | Vial | Inj | Name      | Retention Time(min) | Area    | %Area | USP Tailing | USP Plate count |
|----------|--------------|------|-----|-----------|---------------------|---------|-------|-------------|-----------------|
| 1        | Blank        | 15   | 1   | Tadalafil | 3.747               |         |       |             |                 |
| 2        | Std          | 16   | 1   | Tadalafil | 3.707               | 70924   | 12.01 | 1.35        | 2495.12         |
| 3        | Std          | 16   | 1   | Tadalafil | 3.710               | 71491   | 12.00 | 1.37        | 2451.10         |
| 4        | Std          | 16   | 1   | Tadalafil | 3.710               | 71984   | 12.11 | 1.35        | 2443.55         |
| 5        | Std          | 16   | 1   | Tadalafil | 3.710               | 71654   | 12.08 | 1.35        | 2430.43         |
| 6        | B.std        | 16   | 1   | Tadalafil | 3.712               | 70887   | 11.88 | 1.38        | 2594.22         |
| 7        | B.std        | 16   | 1   | Tadalafil | 3.705               | 71079   | 11.78 | 1.37        | 2674.47         |
| 8        | Std          | 16   | 1   | Tadalafil | 3.710               | 71175   | 11.97 | 1.36        | 2457.00         |
| 9        | Accuracy50%  | 17   | 2   | Tadalafil | 3.712               | 35656   | 12.11 | 1.38        | 2444.33         |
| 10       | Accuracy50%  | 17   | 2   | Tadalafil | 3.710               | 35479   | 12.09 | 1.39        | 2517.19         |
| 11       | Accuracy50%  | 17   | 1   | Tadalafil | 3.710               | 35981   | 12.26 | 1.36        | 2502.78         |
| 12       | Accuracy50%  | 17   | 1   | Tadalafil | 3.711               | 34509   | 11.83 | 1.35        | 2578.10         |
| 13       | Accuracy100% | 18   | 1   | Tadalafil | 3.712               | 73971   | 12.38 | 1.45        | 2439.62         |
| 14       | Accuracy100% | 18   | 2   | Tadalafil | 3.712               | 70701   | 11.91 | 1.38        | 2578.28         |
| 15       | Accuracy100% | 18   | 2   | Tadalafil | 3.712               | 70798   | 11.95 | 1.37        | 2552.37         |
| 16       | Accuracy100% | 18   | 1   | Tadalafil | 3.713               | 73129   | 12.28 | 1.42        | 2499.99         |
| 17       | Accuracy150% | 19   | 1   | Tadalafil | 3.709               | 108398  | 12.15 | 1.46        | 2605.04         |
| 18       | Accuracy150% | 19   | 1   | Tadalafil | 3.704               | 108482  | 12.11 | 1.46        | 2703.43         |
| 19       | Accuracy150% | 19   | 2   | Tadalafil | 3.707               | 108588  | 12.09 | 1.44        | 2699.59         |
| 20       | Accuracy150% | 19   | 2   | Tadalafil | 3.706               | 108556  | 12.11 | 1.45        | 2645.74         |
| Mean     |              |      |     |           | 3.711               | 71760.1 |       |             |                 |
| Std.Dev. |              |      |     |           | 0.009               | 24381.1 |       |             |                 |
| %RSD     |              |      |     |           | 0.24                | 33.98   |       |             |                 |

**High flow variation**

Band broadening and decreased column efficiency can result from high flow liquid chromatography(HPLC). A portion of the sample lags behind at high flow rates because the analytic adsorbs to the stationary phase. Band broadening may

result from this. High pressure, which can be brought on by leaks or air in the pump heads, can also result from high flow rates..



|   | Peak Name  | RT    | Area   | % Area | USP Tailing | USP Plate Count | Resolution |
|---|------------|-------|--------|--------|-------------|-----------------|------------|
| 1 | Tadalafil  | 3.715 | 72606  | 12.69  | 1.60        | 3807.33         |            |
| 2 | Sildenafil | 4.664 | 499756 | 87.31  | 1.68        | 2517.22         | 3.30       |

**FIG10:Chromatogram for High flow variation**

**Table 10 : High flow variation Data for Sildenafil**

| S. no.   | Sample Name | Vial | Inj | Name       | RetentionTime(min) | Area     | %Area | USPTailing | USPPlateCount |
|----------|-------------|------|-----|------------|--------------------|----------|-------|------------|---------------|
| 1        | bLANK       | 60   | 1   | Sildenafil | 4.707              |          |       |            |               |
| 2        | STD         | 61   | 1   | Sildenafil | 4.266              | 500539   | 88.85 | 1.67       | 2603.91       |
| 3        | STD         | 61   | 4   | Sildenafil | 4.272              | 501786   | 88.77 | 1.70       | 2589.91       |
| 4        | STD         | 61   | 2   | Sildenafil | 4.267              | 503425   | 88.79 | 1.69       | 2555.72       |
| 5        | STD         | 61   | 3   | Sildenafil | 4.271              | 501535   | 88.67 | 1.69       | 2598.47       |
| 6        | STD         | 61   | 5   | Sildenafil | 4.279              | 501794   | 88.76 | 1.71       | 2480.66       |
| Mean     |             |      |     |            | 4.344              | 501816.1 |       |            |               |
| Std.Dev. |             |      |     |            | 0.178              | 1036.8   |       |            |               |
| %RSD     |             |      |     |            | 4.10               | 0.21     |       |            |               |

**Table 11 :High flow variation Data for Tadalafil**

| S.No     | Sample Name | Vial | Inj | Name      | Retention Time(min) | Area    | %Area | USP Tailing | USP Plate Count |
|----------|-------------|------|-----|-----------|---------------------|---------|-------|-------------|-----------------|
| 1        | bLANK       | 60   | 1   | Tadalafil | 3.747               |         |       |             |                 |
| 2        | STD         | 61   | 1   | Tadalafil | 3.398               | 62783   | 11.15 | 1.51        | 4371.51         |
| 3        | STD         | 61   | 5   | Tadalafil | 3.408               | 63531   | 11.24 | 1.62        | 4160.89         |
| 4        | STD         | 61   | 3   | Tadalafil | 3.405               | 64091   | 11.33 | 1.61        | 4269.37         |
| 5        | STD         | 61   | 2   | Tadalafil | 3.397               | 63527   | 11.21 | 1.58        | 4199.26         |
| 6        | STD         | 61   | 4   | Tadalafil | 3.403               | 63458   | 11.23 | 1.59        | 4209.03         |
| Mean     |             |      |     |           | 3.460               | 63478.0 |       |             |                 |
| Std.Dev. |             |      |     |           | 0.141               | 465.0   |       |             |                 |
| %RSD     |             |      |     |           | 4.07                | 0.73    |       |             |                 |

### LOD & LOQ

The threshold at which an analyte present within a sample can be recognized, yet not consistently quantified with a precise numerical value, is designated as the detection limit pertinent to a particular analytical procedure. The limit of


detection (LOD) can be ascertained through the equation  $L = 3.3 \times \sigma/S$ , where  $\sigma$  denotes the variability or standard deviation of the calibration curve intercepts.  $S$  represents the gradient of the linear response plot. This phenomenon occurs because the assessment of the detection limit can be executed through visual inspection. The signal-to-noise ratio constitutes the comparative measure of signal strength against background noise; it encompasses both the slope and dispersion of the response function.

The quantitation threshold for any particular analytical technique is defined as the lowest concentration of the analyte that can be consistently identified within a sample and quantified with an adequate level of accuracy and precision. In instances involving trace quantities of chemical substances within a sample matrix, the limit of quantitation serves as a critical parameter in quantitative assessments, particularly utilized for the identification and quantification of pollutants and their degradation products. The limit of quantitation, under specified conditions, may be determined through the application of the following equation:

Where,  $\delta$  = standard deviation of response  $LOQ = 10 \times \delta/S$


$S$  = Average of slope of the calibration curves.

Through the application of progressively reduced volumes of the standard solutions within the methodologies delineated, the limits of detection (LOD) and limits of quantification (LOQ) for the novel analytical technique were ascertained. The LOQ signifies the minimum concentration of the analyte at which quantification can be performed with a degree of accuracy and precision that is deemed satisfactory, while considering the signal-to-noise ratio; conversely, the LOD represents the minimum concentration that can be identified and differentiated, also taking into account the signal-to-noise ratio. The established LOD values for both Tadalafil and sildenafil were determined to be 1.65 parts per million (PPM). Furthermore, Tadalafil and sildenafil were evaluated to possess a LOQ of 5 PPM.



**Fig 11: Normal chromatogram LOD & LOQ for std**

Mobile phase: Acetate Buffer : Methanol 10:90  
 Column: ZORBAX C18 (250 x 4.6 , 5  $\mu$ )  
 Flow :0.7 mL/min  
 Con:10 ppm  
 Diluent:MP




**Fig 12: Normal chromatogram LOD & LOQ for sample**

**Table 12: LOD & LOQ Of Sildenafil and Tadalafil**

|          | Sample Name  | Vial | Inj | Name       | Retention Time(min) | Area     | %Area | USP Tailing | USPPlate Count  |
|----------|--------------|------|-----|------------|---------------------|----------|-------|-------------|-----------------|
| 1        | Blank        | 60   | 1   | Sildenafil | 4.707               |          |       |             |                 |
| 2        | Std          | 61   | 1   | Sildenafil | 4.607               | 530169   | 88.79 | 1.60        | 4575.38         |
| 3        | Std          | 61   | 1   | Sildenafil | 4.607               | 529852   | 88.78 | 1.60        | 4544.34         |
| 4        | Std          | 61   | 1   | Sildenafil | 4.600               | 526627   | 88.76 | 1.59        | 4503.01         |
| 5        | Std          | 61   | 1   | Sildenafil | 4.601               | 528059   | 88.70 | 1.59        | 4532.10         |
| 6        | Std          | 61   | 1   | Sildenafil | 4.605               | 526954   | 88.78 | 1.60        | 4527.37         |
| 7        | LOQPrecision | 62   | 5   | Sildenafil | 4.599               | 54520    | 88.64 | 1.35        | 4025.85         |
| 8        | LOQPrecision | 62   | 4   | Sildenafil | 4.598               | 54323    | 88.82 | 1.35        | 4026.30         |
| 9        | LOQPrecision | 62   | 2   | Sildenafil | 4.603               | 55097    | 88.87 | 1.38        | 4003.02         |
| 10       | LOQPrecision | 62   | 1   | Sildenafil | 4.605               | 55051    | 88.83 | 1.39        | 3992.06         |
| 11       | LOQPrecision | 62   | 3   | Sildenafil | 4.602               | 54487    | 88.66 | 1.34        | 3947.65         |
| 12       | LOQ5ppm      | 62   | 1   | Sildenafil | 4.614               | 54257    | 88.49 | 1.37        | 3959.96         |
| 13       | LOQ7ppm      | 63   | 1   | Sildenafil | 4.609               | 74820    | 88.53 | 1.39        | 4045.58         |
| 14       | LOQ10ppm     | 64   | 1   | Sildenafil | 4.604               | 106863   | 88.77 | 1.43        | 4084.65         |
| 15       | LOD1.65ppm   | 65   | 1   | Sildenafil | 4.611               | 16812    | 87.57 | 1.22        | 4142.76         |
| Mean     |              |      |     |            | 4.611               | 226277.9 |       |             |                 |
| Std.Dev. |              |      |     |            | 0.027               | 234367.2 |       |             |                 |
| %RSD     |              |      |     |            | 0.58                | 103.57   |       |             |                 |
|          | SampleName   | Vial | Inj | Name       | RetentionTime(min)  | Area     | %Area | USP Tailing | USP Plate Count |
| 1        | Blank        | 60   | 1   | Tadalafil  | 3.747               |          |       |             |                 |
| 2        | Std          | 61   | 1   | Tadalafil  | 3.772               | 66906    | 11.21 | 1.27        | 7373.52         |
| 3        | Std          | 61   | 1   | Tadalafil  | 3.772               | 66627    | 11.22 | 1.28        | 7375.34         |
| 4        | Std          | 61   | 1   | Tadalafil  | 3.770               | 67255    | 11.30 | 1.27        | 7460.49         |
| 5        | Std          | 61   | 1   | Tadalafil  | 3.770               | 66680    | 11.24 | 1.27        | 7533.31         |
| 6        | Std          | 61   | 1   | Tadalafil  | 3.774               | 66972    | 11.22 | 1.27        | 7336.34         |
| 7        | LOQPrecision | 62   | 5   | Tadalafil  | 3.731               | 6989     | 11.36 | 1.15        | 4800.14         |
| 8        | LOQ5ppm      | 62   | 1   | Tadalafil  | 3.752               | 7055     | 11.51 | 1.16        | 4997.10         |
| 9        | LOQPrecision | 62   | 4   | Tadalafil  | 3.731               | 6837     | 11.18 | 1.14        | 4942.37         |
| 10       | LOQPrecision | 62   | 3   | Tadalafil  | 3.734               | 6967     | 11.34 | 1.16        | 4731.83         |
| 11       | LOQPrecision | 62   | 1   | Tadalafil  | 3.738               | 6925     | 11.17 | 1.17        | 4856.98         |
| 12       | LOQPrecision | 62   | 2   | Tadalafil  | 3.736               | 6898     | 11.13 | 1.16        | 4994.09         |
| 13       | LOQ7ppm      | 63   | 1   | Tadalafil  | 3.748               | 9694     | 11.47 | 1.16        | 5122.60         |
| 14       | LOQ10ppm     | 64   | 1   | Tadalafil  | 3.746               | 13525    | 11.23 | 1.17        | 5376.03         |
| 15       | LOD1.65ppm   | 65   | 1   | Tadalafil  | 3.744               | 2385     | 12.43 | 1.24        | 4872.75         |
| Mean     |              |      |     |            | 3.751               | 28693.9  |       |             |                 |
| Std.Dev. |              |      |     |            | 0.016               | 29633.1  |       |             |                 |
| %RSD     |              |      |     |            | 0.44                | 103.27   |       |             |                 |

**Intermediate Precision**

Intermediate precision pertains to the performance of the methodology, encompassing both qualitative and quantitative aspects, within a singular laboratory, while also accounting for variations between instruments and across different days, and subsequently computing the percentage relative standard deviation (% RSD) of the assay.



|   | Peak Name  | RT    | Area   | % Area | USP Tailing | USP Plate Count | Resolution |
|---|------------|-------|--------|--------|-------------|-----------------|------------|
| 1 | Tadalafil  | 3.690 | 72453  | 11.22  | 1.79        | 3550.15         |            |
| 2 | Sildenafil | 4.635 | 573041 | 88.78  | 1.91        | 1550.56         | 2.99       |

Fig 13:Normal chromatogram Intermediate Precision

Table 13:Intermediate Precision Data for Sildenafil

| SR.NO    | Sample Name | Vial | Inj | Name       | Retention Time(min) | Area     | %Area | USP Tailing | USP Plate Count |
|----------|-------------|------|-----|------------|---------------------|----------|-------|-------------|-----------------|
| 1        | Blank       | 60   | 1   | Sildenafil | 4.707               |          |       |             |                 |
| 2        | std         | 61   | 1   | Sildenafil | 4.631               | 570525   | 88.66 | 1.90        | 1505.37         |
| 3        | std         | 61   | 1   | Sildenafil | 4.635               | 573041   | 88.78 | 1.91        | 1550.56         |
| 4        | std         | 61   | 1   | Sildenafil | 4.635               | 572444   | 88.77 | 1.90        | 1636.58         |
| 5        | std         | 61   | 1   | Sildenafil | 4.637               | 572930   | 88.76 | 1.93        | 1839.75         |
| 6        | B.std       | 61   | 1   | Sildenafil | 4.622               | 578782   | 88.79 | 1.97        | 2675.49         |
| 7        | std         | 61   | 1   | Sildenafil | 4.634               | 570888   | 88.78 | 1.94        | 1817.19         |
| 8        | M.P.Test1   | 62   | 1   | Sildenafil | 4.634               | 561378   | 88.80 | 1.93        | 1895.65         |
| 9        | M.P.Test2   | 63   | 1   | Sildenafil | 4.631               | 569697   | 88.83 | 1.93        | 1904.55         |
| 10       | M.P.Test3   | 64   | 1   | Sildenafil | 4.631               | 562553   | 88.83 | 1.93        | 2113.00         |
| 11       | M.P.Test4   | 65   | 1   | Sildenafil | 4.628               | 559283   | 88.80 | 1.95        | 2283.22         |
| 12       | M.P.Test5   | 66   | 1   | Sildenafil | 4.624               | 578762   | 89.17 | 1.91        | 2766.15         |
| 13       | M.P.Test6   | 67   | 1   | Sildenafil | 4.620               | 565896   | 88.47 | 1.83        | 4056.30         |
| Mean     |             |      |     |            | 4.636               | 569681.7 |       |             |                 |
| Std.Dev. |             |      |     |            | 0.022               | 6318.3   |       |             |                 |
| %RSD     |             |      |     |            | 0.47                | 1.11     |       |             |                 |

### Method Precision - Sildenafil

|  |     | System Suitability |       |        |        |         |        |
|--|-----|--------------------|-------|--------|--------|---------|--------|
|  |     | Area               | R.T.  | B.std  |        | % Assay |        |
|  |     | 570525             | 4.631 | 570525 | Test-1 | 98.1    |        |
|  |     | 573041             | 4.635 | 573041 | Test-2 | 99.6    |        |
|  |     | 572444             | 4.635 | 572444 | Test-3 | 98.4    |        |
|  |     | 570888             | 4.634 | 570888 | Test-4 | 97.8    |        |
|  |     | 572930             | 4.637 | 572930 | Test-5 | 102.2   |        |
|  | Avg | 571966             | 4.635 | B.std  | 578782 | Test-6  | 98.9   |
|  | sd  | 1178.1             | 0.0   |        | Avg    | 99.2    |        |
|  | rsd | 0.21               | 0.03  | Avg    | 573102 | sd      | 1.6158 |
|  |     |                    |       | sd     | 2975.6 | rsd     | 1.63   |
|  |     |                    |       | rsd    | 0.52   |         |        |

**Table 13: Intermediate Precision Data for Sildenafil**


|          | Samle Name | Vial | Inj | Name      | Retention Time (min) | Area    | %Area | USP Tailing | USP Plate count |
|----------|------------|------|-----|-----------|----------------------|---------|-------|-------------|-----------------|
| 1        | blank      | 60   | 1   | Tadalafil | 3.747                |         |       |             |                 |
| 2        | std        | 61   | 1   | Tadalafil | 3.688                | 7298    | 11.34 | 1.78        | 3765.97         |
| 3        | std        | 61   | 1   | Tadalafil | 3.690                | 7245    | 11.22 | 1.79        | 3550.15         |
| 4        | std        | 61   | 1   | Tadalafil | 3.690                | 7245    | 11.23 | 1.78        | 3737.86         |
| 5        | std        | 61   | 1   | Tadalafil | 3.688                | 72160   | 11.22 | 1.82        | 4240.34         |
| 6        | B.std      | 61   | 1   | Tadalafil | 3.686                | 73095   | 11.21 | 1.84        | 4826.72         |
| 7        | std        | 61   | 1   | Tadalafil | 3.692                | 72536   | 11.24 | 1.82        | 3807.66         |
| 8        | M.P.Test1  | 62   | 1   | Tadalafil | 3.690                | 70832   | 11.20 | 1.81        | 4048.09         |
| 9        | M.P.Test2  | 63   | 1   | Tadalafil | 3.690                | 71643   | 11.17 | 1.81        | 4066.10         |
| 10       | M.P.Test3  | 64   | 1   | Tadalafil | 3.690                | 70733   | 11.17 | 1.82        | 4345.63         |
| 11       | M.P.Test4  | 65   | 1   | Tadalafil | 3.690                | 70556   | 11.20 | 1.83        | 4584.14         |
| 12       | M.P.Test5  | 66   | 1   | Tadalafil | 3.688                | 70267   | 10.83 | 1.66        | 5180.63         |
| 13       | M.P.Test6  | 67   | 1   | Tadalafil | 3.689                | 73785   | 11.53 | 1.77        | 6245.09         |
| Mean     |            |      |     |           | 3.694                | 71958.2 |       |             |                 |
| Std.Dev. |            |      |     |           | 0.016                | 1137.8  |       |             |                 |
| %RSD     |            |      |     |           | 0.44                 | 1.58    |       |             |                 |

**Table 14: Intermediate Precision Data for Tadalafil**

| Intermediate Precision - Tadalafil |     |                    |       |       |       |        |         |  |  |
|------------------------------------|-----|--------------------|-------|-------|-------|--------|---------|--|--|
|                                    |     | System Suitability |       |       |       |        |         |  |  |
|                                    |     | Area               | R.T.  |       | B.std |        | % Assay |  |  |
|                                    |     | 72984              | 3.688 |       | 72984 | Test-1 | 97.7    |  |  |
|                                    |     | 72453              | 3.69  |       | 72453 | Test-2 | 98.8    |  |  |
|                                    |     | 72160              | 3.688 |       | 72160 | Test-3 | 97.5    |  |  |
|                                    |     | 72536              | 3.692 |       | 72536 | Test-4 | 97.3    |  |  |
|                                    |     | 72453              | 3.69  |       | 72453 | Test-5 | 96.9    |  |  |
|                                    | Avg | 72517              | 4     | B.std | 73095 | Test-6 | 96.9    |  |  |
|                                    | sd  | 297.5              | 0.0   |       |       | Avg    | 97.5    |  |  |
|                                    | rsd | 0.41               | 0.04  | Avg   | 72614 | sd     | 0.7055  |  |  |
|                                    |     |                    |       | sd    | 355.6 | rsd    | 0.72    |  |  |
|                                    |     |                    |       | rsd   | 0.49  |        |         |  |  |

**Solution stability**

The concept of solution stability pertains to the degree of stability exhibited by both the standard solution and the extracted sample solution, or the solution prepared for injection derived from the sample or matrix, and analyzed in accordance with the established methodology. The standard and sample solutions ought to be maintained under room temperature conditions or refrigerated environments, contingent upon the inherent stability characteristics of the standard and sample solutions.




SampleName:TEST;

DateAcquired:10/14/20234:

11:58PMIST;

Vial:62;Injection:1



SampleName:B.STD;

DateAcquired:10/14/20234:

20:56PMIST;

Vial:61;Injection:1

Fig 14:Normal chromatogram Solution stability

Table 15 : Solution stability Sildenafil

| SR.NO    | Sample Name | Vial | Inj | Name       | Retention Time(min) | Area     | %Area | USPTailing | USPPlateCount |
|----------|-------------|------|-----|------------|---------------------|----------|-------|------------|---------------|
| 1        | BLANK       | 60   | 1   | Sildenafil | 4.707               |          |       |            |               |
| 2        | B.STD       | 61   | 1   | Sildenafil | 4.632               | 572142   | 88.86 | 1.86       | 1525.77       |
| 3        | STD         | 61   | 1   | Sildenafil | 4.632               | 574563   | 88.83 | 1.85       | 1678.53       |
| 4        | STD         | 61   | 1   | Sildenafil | 4.626               | 571258   | 88.78 | 1.87       | 1594.16       |
| 5        | STD         | 61   | 1   | Sildenafil | 4.630               | 569867   | 88.79 | 1.82       | 1734.33       |
| 6        | STD         | 61   | 1   | Sildenafil | 4.627               | 574885   | 88.87 | 1.88       | 1646.35       |
| 7        | STD         | 61   | 1   | Sildenafil | 4.627               | 574106   | 88.83 | 1.89       | 1713.38       |
| 8        | TEST        | 62   | 1   | Sildenafil | 4.634               | 562212   | 88.85 | 1.83       | 1812.68       |
| Mean     |             |      |     |            | 4.639               | 571290.5 |       |            |               |
| Std.Dev. |             |      |     |            | 0.028               | 4410.9   |       |            |               |
| %RSD     |             |      |     |            | 0.59                | 0.77     |       |            |               |

Table 16 : Solution stability Tadalafil

| SR.NO    | Sample Name | Vial | Inj | Name      | RetentionTime(min) | Area    | %Area | USPTailing | USPPlateCount |
|----------|-------------|------|-----|-----------|--------------------|---------|-------|------------|---------------|
| 1        | BLANK       | 60   | 1   | Tadalafil | 3.747              |         |       |            |               |
| 2        | B.STD       | 61   | 1   | Tadalafil | 3.688              | 71761   | 11.14 | 1.72       | 3224.31       |
| 3        | STD         | 61   | 1   | Tadalafil | 3.687              | 72227   | 11.17 | 1.75       | 2120.06       |
| 4        | STD         | 61   | 1   | Tadalafil | 3.686              | 72020   | 11.13 | 1.72       | 2407.98       |
| 5        | STD         | 61   | 1   | Tadalafil | 3.688              | 71939   | 11.21 | 1.70       | 2698.13       |
| 6        | STD         | 61   | 1   | Tadalafil | 3.686              | 72174   | 11.22 | 1.74       | 2847.57       |
| 7        | STD         | 61   | 1   | Tadalafil | 3.689              | 72246   | 11.17 | 1.73       | 2206.02       |
| 8        | TEST        | 62   | 1   | Tadalafil | 3.690              | 70529   | 11.15 | 1.70       | 3121.31       |
| Mean     |             |      |     |           | 3.695              | 71842.4 |       |            |               |
| Std.Dev. |             |      |     |           | 0.021              | 604.7   |       |            |               |
| %RSD     |             |      |     |           | 0.57               | 0.84    |       |            |               |

### Wavelength variation

More importantly, in order to optimize the fluorescent funnel, the absorption spectrum of the molecule of interest must be examined. This reduces the spectral interference produced by the error in measurement of the detector alone.



**Table 17: Wavelength variation**

| Wavelength Variation - Sildenafil - 278 nm |     |                    |       | Wavelength Variation - Sildenafil - 282 nm |     |                    |       |
|--|-----|--------------------|-------|--|-----|--------------------|-------|
|  |     | System Suitability |       |  |     | System Suitability |       |
|  |     | Area               | R.T.  |  |     | Area               | R.T.  |
|  |     | 633099             | 4.674 |  |     | 499756             | 4.664 |
|  |     | 631880             | 4.684 |  |     | 498540             | 4.668 |
|  |     | 632273             | 4.685 |  |     | 498682             | 4.672 |
|  |     | 630270             | 4.685 |  |     | 499589             | 4.666 |
|  |     | 632241             | 4.682 |  |     | 499019             | 4.667 |
|  | Avg | 631953             | 4.684 |  | Avg | 499117             | 4.668 |
|  | sd  | 1041.2             | 0.0   |  | sd  | 539.2              | 0.0   |
|  | rsd | 0.16               | 0.03  |  | rsd | 0.11               | 0.06  |

| Wavelength Variation - Sildenafil - 278 nm |     |                    |       | Wavelength Variation - Sildenafil - 282 nm |     |                    |       |
|--|-----|--------------------|-------|--|-----|--------------------|-------|
|  |     | System Suitability |       |  |     | System Suitability |       |
|  |     | Area               | R.T.  |  |     | Area               | R.T.  |
|  |     | 633099             | 4.674 |  |     | 499756             | 4.664 |
|  |     | 631880             | 4.684 |  |     | 498540             | 4.668 |
|  |     | 632273             | 4.685 |  |     | 498682             | 4.672 |
|  |     | 630270             | 4.685 |  |     | 499589             | 4.666 |
|  |     | 632241             | 4.682 |  |     | 499019             | 4.667 |
|  | Avg | 631953             | 4.684 |  | Avg | 499117             | 4.668 |
|  | sd  | 1041.2             | 0.0   |  | sd  | 539.2              | 0.0   |
|  | rsd | 0.16               | 0.03  |  | rsd | 0.11               | 0.06  |

### Dissolution study

The novel high-performance liquid chromatography (HPLC) methodology employed for the examination of dissolution samples pertaining to the pharmaceutical formulations demonstrated its proficiency in effectively segregating the primary peak from the confounding peaks. Loss due to degradation was handled by using dissolution media to perform dissolution analysis.

**Table 19: Dissolution study**

|         | Std      | Disso spl |
|---------|----------|-----------|
|         | 0.759    | 0.793     |
|         | 0.758    | 0.789     |
|         | 0.758    |           |
| Average | 0.758    | 0.791     |
| SD      | 0.000577 |           |
| RSD     | 0.076134 |           |

### Results of assay of marketed formulation

By conducting a mass determination of twenty tablets and calculating their mean weight, the mass of an individual tablet was subsequently transferred into a 100mL volumetric flask, followed by the addition of 50mL of diluents, after which the flask was subjected to sonication for a duration of 25 minutes and subsequently filtered. A volume of one millilitre from the filtered solution was then carefully pipetted into a 10 millilitre volumetric flask, and the remaining volume was adjusted to the mark with the same diluents.

**Table 20: Assay of marketed formulation**

| Brand     | Drug       | Sample peak area | Standard peak area | Labelled amount (mg/tab) | % Assay | RSD  |
|-----------|------------|------------------|--------------------|--------------------------|---------|------|
| Sildalist | Sildenafil | 789296           | 799456             | 100                      | 99.73   | 0.91 |
|           | Tadalafil  | 108588           | 108690             | 20                       | 100.45  | 1.21 |

### Conclusion

An uncomplicated, exacting, and exceptionally sensitive RP-HPLC technique is articulated for the simultaneous quantification of Sildenafil and Tadalafil in pharmaceutical formulations. The method yields significant resolution

between the analytes within a concise analytical duration. Ultimately, it was concluded that the technique is suitable for the evaluation of standard quality control samples.

### Acknowledgements

The Autor wish to thank Sigma-aldrich (USA) for supplying the samples of tadalafil Tadalafil and Sildenafil within the required time so as to enable us to complete this research paper quickly. Also thanks to KPGU Vadodara for provide support and facilities for that work.

### References

1. Webb, D.J.; Freestone, S.; Allen, M.J.; Muirhead, G.J. (March 4, 1999). "Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist". *Am. J. Cardiol.* 83 (5A): 21C–28C. doi:10.1016/S0002-9149(99)00044-2. PMID 10078539
2. The Journal of Urology, Volume 177, Issue 3, Pages 1071-1077 K. McVary, W. Monnig, J. Camps Jr., J. Young, L. Tseng, G. van den Ende.
3. J. D. Corbin and S. H. Sharron. "Molecular Biology and Pharmacology of PDE-5-Inhibitor Therapy for Erectile Dysfunction". *J. Androl.* 24: S38-S41.
4. J. D. Corbin and S. H. Sharron. "Molecular Biology and Pharmacology of PDE-5-Inhibitor Therapy for Erectile Dysfunction". *J. Androl.* 24: S38-S41.
5. C.Ho and G.L.Chen, stability indicating HPLC Assay methods for Drug in Pharmaceutical dosage forms: Part-I, *J Food Drug Anal.*4(1996)271-292.
6. Samuel R.Gartz. PhD. E.D. Drugs and analogs; Characterization of phosphodiesterase- 5 Inhibitors in suspect counterfeit and herbal products. USP Annual Scientific Meeting. 2007.
7. World Health Organization (WHO). National Policy on Traditional Medicine and Regulation of Herbal Medicines. Geneva: Report of WHO global survey. 2005.
8. Kannappan N, Deepth Y, Divya Y, Shashihanth MR. Method Development and Validation of Stability-indicating Methods for assay of Tadalafil and Sildenafil Citrate by HPLC. *Int J ChemTech Res.* 2010; 2(1): 329-333.
9. Amr MB, Abd El-Aziz B AE, Nesrine TL. Stability indicating methods for the determination of sildenafil in the presence of its degradation product. *Int J Compr Pharma.* 2011; 2 (7).
10. International Conference on Harmonization (ICH). Harmonized Tripartite Guideline Validation Of Analytical Procedures :Text and methodology Q2(R1) Current Step 4 version Parent Guideline October 1994 page11,2.